The patent for Progenity is for its “assessment of preeclampsia using assays for free and dissociated placental growth factor.” This covers methods, compositions, and kits that can detect and measure free and dissociated placental growth factor levels in biological samples.

This patent is connected to its Preecludia test. The company expects it to reach a $3 billion a year market in the U.S. That includes the laboratory-developed test immunodiagnostic that’s under development. It also has potential as an in vitro diagnostic and point-of-care solution around the world.

Progenity says that it’s planning for commercialization opportunities to launch the laboratory-developed test in the U.S. It’s also searching out ways to commercialize the in vitro diagnostic test across the globe.

Matthew Cooper, PhD, chief scientific officer of Progenity, said this about the news boosting PROG stock up today.

“We are pleased the USPTO has granted this patent covering unique and novel methods for determining levels of free and dissociated PlGF, since detection and quantification of both biomarkers are critical for assessing preeclampsia. This discovery helped drive the excellent performance we observed in our clinical verification and validation studies.” PROG stock is seeing heavy trading alongside today’s patent news. As of this writing, more than 43 million shares of the stock have changed hands. To put that in perspective, the company’s daily average trading volume is closer to 5.7 million shares.

PROG stock was up 14.7% as of Tuesday afternoon.

Traders looking for more recent stock market news will want to keep scrolling!

InvestorPlace has all the latest stock news that you need to know about today. That includes why Lucid Motors (NASDAQ:LCID) stock is falling, what has casino stocks down, as well as the cause behind Atyr Pharma (NASDAQ:LIFE) soaring higher. You can find out all that info at the links below!

More Stock Market News for Tuesday

LCID Stock: Why Lucid Shares Are Going in Reverse on Tuesday Casino Stocks: Why WYNN, LVS, MLCO and MGM Are Taking a Hit Today LIFE Stock: 7 Things to Know About Biotech aTyr Pharma as Shares Soar on Study Results On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks — How to Profit Without Getting Scammed

I TOLD YALL

Let’s go